4-(9-isopropyl-9H-purin-6-yl)phenol | 1235035-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(9-isopropyl-9H-purin-6-yl)phenol
• 英文别名: 4-(9-propan-2-ylpurin-6-yl)phenol
• CAS: 1235035-60-5
• 化学式: C₁₄H₁₄N₄O
• 分子量: 254.291
• InChiKey: SCRYAZZFTCWFHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-bis(trifluoromethyl)phenyl azide 、 4-(9-isopropyl-9H-purin-6-yl)phenol 在 silver hexafluoroantimonate 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 12.0h， 以52%的产率得到N-[3,5-bis(trifluoromethyl)phenyl]-5-hydroxy-2-(9-isopropyl-9H-purin-6-yl)aniline
  参考文献：
  名称：

  Hydrogen-Bond-Assisted Controlled C–H Functionalization via Adaptive Recognition of a Purine Directing Group

  摘要：

  We have developed the Rh-catalyzed selective C-H functionalization of 6-arylpurines, in which the purine moiety directs the C-H bond activation of the aryl pendant. While the first C-H amination proceeds via the N1-chelation assistance, the subsequent second C-H bond activation takes advantage of an intramolecular hydrogen-bonding interaction between the initially formed amino group and one nitrogen atom, either N1 or N7, of the purinyl part. Isolation of a rhodacycle intermediate and the substrate variation studies suggest that N1 is the main active site for the C-H functionalization of both the first and second amination in 6-arylpurines, while N7 plays an essential role in controlling the degree of functionalization serving as an intramolecular hydrogen-bonding site in the second amination process. This pseudo-Curtin-Hammett situation was supported by density functional calculations, which suggest that the intramolecular hydrogen-bonding capability helps second amination by reducing the steric repulsion between the first installed ArNH and the directing group.

  DOI：

  10.1021/ja4118472
• 作为产物：
  描述：

  9-isopropyl-6-(4-(tetrahydro-2H-pyran-2-yloxy)phenyl)-9H-purine 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以94%的产率得到4-(9-isopropyl-9H-purin-6-yl)phenol
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  在一个方面，本发明提供了一种具有式I的化合物；其中变量X1a、X1b、X1c、X1d、Q、A、R1、B、L、E和下标m和n的含义如本文所述。在另一个方面，本发明提供了包括式I化合物的药物组合物，以及使用式I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过度表达所特征的疾病和状况（例如癌症、血小板增多症等）的方法。

  公开号：

  WO2010080503A1

文献信息

• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Baell Jonathan Bayldon

  公开号：US20100210622A1

  公开（公告）日：2010-08-19

  In one aspect, the present invention provides for a compound of Formula I in which the variable X 1a , X 1b , X 1c , X 1d , Q, A, R 1 , B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-x L proteins.

  在一个方面，本发明提供了一种式子为I的化合物，其中变量X1a，X1b，X1c，X1d，Q，A，R1，B，L，E和下标m和n的含义如此处所述。在另一个方面，本发明提供了包含式子I化合物的制药组合物，以及使用式子I化合物治疗由Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的表达或过表达所特征的疾病和病状（例如癌症，血小板增多症等）的方法。
• Heterocyclic compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US08232273B2

  公开（公告）日：2012-07-31

  In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.

  在一个方面，本发明提供了一种公式I的化合物，其中变量X1a、X1b、X1c、X1d、Q、A、R1、B、L、E和下标m和n的含义如此处所述。在另一个方面，本发明提供了包含公式I化合物的制药组合物，以及使用公式I化合物治疗表达或过度表达Bcl-2抗凋亡蛋白（例如抗凋亡Bcl-xL蛋白）的疾病和状况（例如癌症、血小板增多症等）的方法。
• US8232273B2
  申请人：——

  公开号：US8232273B2

  公开（公告）日：2012-07-31